Dengue Vaccine Effective in Children in Endemic Regions — Physician’s First Watch
Dengue Vaccine Effective in Children in Endemic Regions
By Kelly Young
A vaccine candidate against the dengue virus showed efficacy in children in Asia, according to a phase-III trial published in the Lancet.
Over 10,000 children (aged 2 to 14 years) were randomized to receive recombinant, chimeric, live attenuated tetravalent dengue vaccine (three doses 6 months apart) or placebo.
During 25 months' surveillance, the vaccine was 56.5% effective. The vaccine was not effective against serotype 2. Efficacy was lower in younger than in older children, "which is of concern," a commentator writes, since younger children are at higher risk.
She concludes: "For the moment, [this] vaccine is the best we have. However, with a 56% efficacy this vaccine will never be a single solution. Continued support for the development of other novel strategies, including drugs, improved case management, insecticides, and new approaches to vector control, is needed before effective dengue control becomes a credible prospect."